Teva Biosimilars | Teva Global Commitment

Our focus on biosimilars

Biosimilars are a natural progression for Teva, following its role in the development of the generic medicine industry over the past 40 years—combining a strength in generics with a knowledge of innovative medicines.

Committed to advancing manufacturing

Teva has innovative facilities for manufacturing biosimilars, including a plant in Ulm, Germany.¹

Committed to offering a robust portfolio

Teva has 9 approved biosimilars—and more in our pipeline—across critical therapeutic areas such as hematology, immunology, oncology, and ophthalmology.

Committed to cost-effectiveness

With 9 currently approved biosimilars, Teva is already delivering more than $3 billion in global annual savings.

Committed to delivering more

Teva has identified key partners with deep expertise in research and development to cost-effectively deliver more biosimilars to patients.²

Committed to precision

Teva deploys state-of-the-art analytical methods to facilitate the development process and ensure our place at the forefront of biosimilar innovation.

Committed to continuity of care

Teva is focused on achieving a seamless transition experience for patients—offering, when needed, support programs for guidance on access, affordability, and adherence.

our mission

Teva Biosimilars is more than a name. We are a heritage of excellence. A commitment to expanding access. A reputation for quality. A promise of reliability.

Our capabilities

At Teva, we’ve spent the last century preparing for what’s happening right now.

53

manufacturing
sites

27

countries

Teva commands the largest fully integrated manufacturing and delivery network in the pharmaceutical industry.

48,000

suppliers

Teva offers one of the largest, most dependable supply chains in the world.

200 million

patients served
every day

1 of 14 generic prescriptions in the United States is filled with a Teva product.

Teva has a highly rated cGMP compliance record as assessed by global regulatory bodies.

$500 million

invested

Teva is driving a path forward with advanced manufacturing technology to efficiently produce high-quality biosimilar medicines.

Over

120 years

With more than 120 years of pharmaceutical experience, Teva is uniquely positioned to offer one of the largest portfolios of high-quality, affordable biosimilars across a range of therapeutic areas.

REFERENCES:

1. Pharmaceutical Technology. Teva Pharmaceuticals sterile manufacturing facility, Ulm. Accessed February 6, 2025. https://www.pharmaceutical-technology.com/projects/teva-pharmaceuticals-sterile-manufacturing-ulm/?cf-view
2. Formycon. Health Canada approves FYB201/Ranopto^® (ranibizumab), a biosimilar to Lucentis^®. Accessed February 6, 2025. https://www.formycon.com/en/blog/press-release/canada-approval-fyb201/

See our portfolio of biosimilars

Our portfolio of products is constantly evolving.

TEVA GLOBAL BIOSIMILARS PORTFOLIO

Teva GLOBAL Commitment